Anti-alarmins in asthma: targeting the airway epithelium with next-generation biologics
CM Porsbjerg, A Sverrild, CM Lloyd… - European …, 2020 - Eur Respiratory Soc
Monoclonal antibody therapies have significantly improved treatment outcomes for patients
with severe asthma; however, a significant disease burden remains. Available biologic …
with severe asthma; however, a significant disease burden remains. Available biologic …
Anti-alarmins in asthma: targeting the airway epithelium with next-generation biologics
CM Porsbjerg, A Sverrild, CM Lloyd… - The European …, 2020 - pubmed.ncbi.nlm.nih.gov
Monoclonal antibody therapies have significantly improved treatment outcomes for patients
with severe asthma; however, a significant disease burden remains. Available biologic …
with severe asthma; however, a significant disease burden remains. Available biologic …
Anti-alarmins in asthma: targeting the airway epithelium with next-generation biologics.
CM Porsbjerg, A Sverrild, CM Lloyd… - The European …, 2020 - europepmc.org
Monoclonal antibody therapies have significantly improved treatment outcomes for patients
with severe asthma; however, a significant disease burden remains. Available biologic …
with severe asthma; however, a significant disease burden remains. Available biologic …
Anti-alarmins in asthma: Targeting the airway epithelium with next-generation biologics
CM Porsbjerg, A Sverrild… - European …, 2020 - researchinformation.amsterdamumc …
Monoclonal antibody therapies have significantly improved treatment outcomes for patients
with severe asthma; however, a significant disease burden remains. Available biologic …
with severe asthma; however, a significant disease burden remains. Available biologic …
Anti-alarmins in asthma: targeting the airway epithelium with next-generation biologics
CM Porsbjerg, A Sverrild, CM Lloyd… - European …, 2020 - Eur Respiratory Soc
Monoclonal antibody therapies have significantly improved treatment outcomes for patients
with severe asthma; however, a significant disease burden remains. Available biologic …
with severe asthma; however, a significant disease burden remains. Available biologic …
Anti-alarmins in asthma: targeting the airway epithelium with next-generation biologics
CM Porsbjerg, A Sverrild, CM Lloyd… - European …, 2020 - research.regionh.dk
Monoclonal antibody therapies have significantly improved treatment outcomes for patients
with severe asthma; however, a significant disease burden remains. Available biologic …
with severe asthma; however, a significant disease burden remains. Available biologic …
[HTML][HTML] Anti-alarmins in asthma: targeting the airway epithelium with next-generation biologics
CM Porsbjerg, A Sverrild, CM Lloyd… - The European …, 2020 - ncbi.nlm.nih.gov
Monoclonal antibody therapies have significantly improved treatment outcomes for patients
with severe asthma; however, a significant disease burden remains. Available biologic …
with severe asthma; however, a significant disease burden remains. Available biologic …
Anti-alarmins in asthma: targeting the airway epithelium with next-generation biologics
CM Porsbjerg, A Sverrild, CM Lloyd… - European Respiratory …, 2020 - cir.nii.ac.jp
抄録< jats: p> Monoclonal antibody therapies have significantly improved treatment
outcomes for patients with severe asthma; however, a significant disease burden remains …
outcomes for patients with severe asthma; however, a significant disease burden remains …
Anti-alarmins in asthma: targeting the airway epithelium with next-generation biologics.
CM Porsbjerg, A Sverrild, CM Lloyd… - The European …, 2020 - europepmc.org
Monoclonal antibody therapies have significantly improved treatment outcomes for patients
with severe asthma; however, a significant disease burden remains. Available biologic …
with severe asthma; however, a significant disease burden remains. Available biologic …